Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis
Status:
Completed
Trial end date:
2018-02-28
Target enrollment:
Participant gender:
Summary
This multiple ascending dose study is to determine safety, tolerability, pharmacokinetics and
immunogenicity of PRX003 in approximately 56 patients with Psoriasis.